Previous Close | 168.55 |
Open | 169.45 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 168.55 - 169.45 |
52 Week Range | 102.30 - 197.20 |
Volume | |
Avg. Volume | 42,161 |
Market Cap | 11.025B |
Beta (5Y Monthly) | 1.37 |
PE Ratio (TTM) | 26.38 |
EPS (TTM) | 6.40 |
Earnings Date | Mar 01, 2022 - Mar 07, 2022 |
Forward Dividend & Yield | 2.00 (1.17%) |
Ex-Dividend Date | Apr 29, 2022 |
1y Target Est | 160.76 |
MELBOURNE, Australia & ST. GALLEN, Switzerland, August 02, 2022--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005796/en/
MELBOURNE, Australia & ST. GALLEN, Switzerland, July 13, 2022--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712006199/en/
EU antitrust regulators are investigating whether Vifor Pharma, which is being acquired by CSL Ltd, disparaged its rival Pharmacosmos in order to hinder competition to its blockbuster iron medicine Ferinject. The European Commission, which opened the probe on Monday, said it has indications of this behaviour going on for many years, which may be in breach of EU rules against companies abusing their dominant position. The EU competition enforcer said it was concerned that Vifor Pharma pursued a misleading communication campaign, primarily targeting healthcare professionals.